WASHINGTON, Jan. 9, 2017 -- CRISPR could potentially engineer super crops, make designer animal models for research and even snip out genetic diseases. Experts say that billions of dollars are at stake. But the landmark technology is embroiled in a legal battle over who controls the patent on CRISPR. The latest episode of Speaking of Chemistry highlights everything you need to know about biotech's biggest patent case -- watch it here: https://youtu.be/IboHEQumDGc.
Speaking of Chemistry is a production of Chemical & Engineering News, a weekly newsmagazine of the American Chemical Society. It's the series that keeps you up to date with the important and fascinating chemistry shaping the world around you. Subscribe to the series at http://bit.ly/ACSReactions, and follow us on Twitter @CENMag.
Subscribe to the series at http://bit.ly/ACSReactions, and follow us on Twitter @ACSreactions to be the first to see our latest videos.
The American Chemical Society is a nonprofit organization chartered by the U.S. Congress. With nearly 157,000 members, ACS is the world's largest scientific society and a global leader in providing access to chemistry-related research through its multiple databases, peer-reviewed journals and scientific conferences. The American Chemical Society does not conduct research, but publishes and publicizes peer-reviewed scientific studies. Its main offices are in Washington, D.C., and Columbus, Ohio.
To automatically receive news releases from the American Chemical Society, contact email@example.com">firstname.lastname@example.org.